“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
LAVAL, Quebec, 16 September 2020 (GLOBE NEWSWIRE) – Acasti Pharma Inc. (“Acasti” or the “Society”) (NASDAQ: ACST – TSX-V: ACST) announced the appointment of Brian D, a leading senior financial position of Ford, as Chief Financial Officer, as of September 14, 2020. Ford assumes day-to-day work in the past through Jean-Fran’ois Boily, Vice President of Finance, who recently resigned.
Brian D. Ford has more than 3 decades of finance, assignment control, and M&A experience in the financial and physical care industries. Mr. Ford is a full CPA-CA who has worked in publicly traded organizations and personal organizations. Mr. Ford has been guilty of devising business recovery strategies, negotiating M&A transactions, and managing quarterly and annual accounting reports. Most recently, Mr. Ford served as Chief Financial Officer and Senior Business Advisor in a personal organization of Ontario-based medical clinics, adding the largest chronic pain management corporation in Canada. During his tenure as CFO and Senior Business Advisor, Mr. Ford took a step forward in the functionality of the company and was instrumental in preparing the company for its IPO. Previously, Mr. Ford was CFO of Telesta Therapeutics. At Telesta Therapeutics, Mr. Ford helped advance a new business plan and was very interested in all equity transactions. Previously, Mr. Ford started his own consulting corporation, Petersford Consulting, where he provided commercial and currency threat monitoring facilities for his clients. Mr. Ford began his career at Ernst & Young, Director of Adaptation, Business Risk Services, developing critical business plans that assessed the earnings and charge profiles that supported budgeting plans and understood the drivers of expansion, is say, with fitness care companies. In addition, at Ernst & Young, Mr. Ford has participated in and led organizations in due diligence engagements similar to mergers and acquisitions or the sale of a business, and has had extensive experience in monetary forecasting. procedural audits. Mr. Ford has a B. A. in Economics, History and English from the University of Guelph and has a Graduate Diploma in Accounting from McGill University. Mr. Ford is a member of the Ontario Institute of Certified Public Accountants.
Jan D’Alvise, CEO of Acasti, said: “We are very happy to name Brian D. Ford as CFO. Brian brings strong leadership skills as well as analytical and monetary capabilities that we will add significant value. As we explore strategic features Brian will take on all the everyday work we used to have through Jean-Fran’ois Boily, who recently resigned, as announced in the past. Boily for his contribution to Acasti and I wish him all the best in his long-term efforts.
Brian D. Ford commented: “I am very happy to settle for the position of CFO at Acasti Pharma and look forward to working effectively with the Acasti team. My delight in valuing strategic opportunities as well as M&A transactions will provide valuable data for Acasti as we compare our functions in the future.
Forward-looking statements
Statements in this press release that are not old or existing statements of fact constitute “forward-looking information” within the meaning of Canadian securities law and “forward-looking statements” within the meaning of United States federal securities law. (collectively, “statements”). These forward-looking statements involve known and unknown dangers, doubts-flaws and other unknown points that may cause the actual effects of Acasti to differ materially from the former effects or from any long-term effects expressed or implied in those forward-looking statements. In addition to statements that explicitly describe those dangers and concerns, readers are encouraged to use statements classified with the terms “believes”, “believes”, “expects”, “intends”, “anticipates”, “potential”, ” should “,” May “,” will “,” anticipate “,” continue “,” target “or other similar dubious and forward-looking expressions. Readers are cautioned not to place undue reliance on such forward-looking statements, that refer only to the date of this press release. The forward-looking statements contained in this press release include, but are not limited to, data or statements about Acasti’s strategy, long-term operations, its review of strategic options, the prospective price of CaPre®, prospects and control plans.
The forward-looking statements contained in this press release are expressly fully qualified through this warning, the “Special Note on Forward-Looking Statements” segment contained in Acasti’s most recent Annual Report on Form 10-K, which will be available on EDGAR on www. sec. gov/edgar/shtml, SEDAR at www. sedar. com, and in the investor segment of Acasti’s online page in www. acastipharma. com. All forward-looking statements contained in this press release are made from Acasti does not undertake to update such forward-looking statements, whether as a result of new information, long-term occasions or otherwise, unless required by law. The forward-looking statements contained herein are also subject to assumptions, hazards and uncertainties that are described from time to time in Acasti’s public filings with the Securities and Exchange Commissions and the Canadian Securities and Exchange Commissions, adding Acasti’s most recent annual report on Form 10K under the name “Risk Factors”.
Neither NASDAQ, TSX Venture Exchange, nor its regulatory service provider (as explained in TSX Venture Exchange policies) is due to the relevance or accuracy of this release.
Contact Acasti: Jan D’Alvise CEO Tel: 450-686-4555 Email: info@acastipharma. comwww. acastipharma. com
Investor Contact: Crescendo Communications, LLC Phone: 212-671-1020 Email: ACST@crescendo-ir. com